Latest News

TAVR for low-risk patients shines at 6 years in NOTION


 

REPORTING FROM EUROPCR 2018

Valve function

The rate of moderate hemodynamic structural valve deterioration through 6 years of follow-up was 3.6% in the TAVR arm, compared with 23.7% in the SAVR group. The rate of nonstructural valve deterioration was 54.0% with TAVR and 57.8% with SAVR, and there were no cases of moderate or severe aortic regurgitation in either group.

The mean aortic valve gradient in the TAVR group went from 44.9 mm Hg at baseline to 12.2 mm Hg at 3 months and to 14.7 mm Hg at 6 years. In the SAVR group, the figures were 44.9 mm Hg, 8.3 mm Hg, and 9.9 mm Hg, respectively.

The effective orifice area in the TAVR group improved from 0.74 cm2 at baseline to 1.37 cm2 at 3 months and to 1.16 cm2 at 6 years. With SAVR, the effective orifice area was 0.74 cm2 at baseline, 1.66 cm2 at 3 months, and 1.53 cm2 at 6 years.

Pages

Recommended Reading

For in-stent restenosis, everolimus-eluting stents topped drug-eluting balloons
MDedge Cardiology
Sapien M3 mitral valve replacement data reported for first 10 patients
MDedge Cardiology
TAVR safe in low-risk aortic stenosis, early data indicate
MDedge Cardiology
FDA recalls HeartMate 3 LV assist device
MDedge Cardiology
Breakthrough in noninvasive assessment of multivessel CAD
MDedge Cardiology
Early PCI now favored in stable CAD
MDedge Cardiology
Renal denervation for hypertension rebounds
MDedge Cardiology
Ad hoc PCI dominates in elderly
MDedge Cardiology
MDedge Cardiocast: Big surprises from EuroPCR
MDedge Cardiology
Single Botox treatment cuts AF for 3 years
MDedge Cardiology